Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Benjamin R. Schrank Image

      Benjamin R. Schrank, M.D., Ph.D.

      Department of CNS - Rad Onc Clinical, Division of Radiation Oncology

      About Dr. Benjamin R. Schrank

      Benjamin Schrank, M.D., Ph.D., is an Assistant Professor in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center and CPRIT Scholar in Cancer Research. He holds a dual appointment in the Department of Epigenetics and Molecular Carcinogenesis at MD Anderson. Dr. Schrank’s research program develops new therapies for treatment-resistant cancers. His discoveries have been published in top-tier journals including Nature, Nature Biomedical Engineering, and Nature Cancer. The goal of his research group is to uncover and target how genome instability reprograms the tumor immune microenvironment. Current projects in the lab include ecDNA-driven immune remodeling and first-in-class antibody-drug conjugate engineering.


      Dr. Schrank holds an M.D. from the Columbia Vagelos College of Physicians and Surgeons and a Ph.D. from the Columbia University Graduate School of Arts & Sciences in New York, NY. His F30-supported doctoral work used Xenopus laevis cell-free systems to elucidate mechanisms of genome instability and repair. His expertise bridges clinical radiation oncology with foundational genetics, bioengineering, and innate immune signaling. Dr. Schrank is an NIH K08 awardee, and his work is currently supported by the National Cancer Institute and the Cancer Prevention & Research Institute of Texas.


      Read More

      In the News

      3D rendering of an antibody-toxin conjugate killing a cancer cell

      MD Anderson researchers develop novel antibody-toxin conjugate

      Medical illustration of antibody conjugates

      Radiation therapy, the immune system and what’s ahead

      Present Title & Affiliation

      Primary Appointment

      Assistant Professor, Department of Epigenetics and Molecular Carcinogenesis, Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Assistant Professor, CNS Radiation Oncology, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Dual/Joint/Adjunct Appointment

      Assistant Professor, Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Assistant Professor, Physician-Scientist, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Education & Training

      Degree-Granting Education

      2020Columbia University Vagelos College of Physicians & Surgeons, New York, NY, US, Medical Scientist Training Program, M.D
      2019Columbia Graduate School of Arts & Sciences, New York, NY, US, Cellular, Molecular, and Biomedical Studies, Ph.D
      2011Brown University/The University of Oxford, Providence, RI, US, Neuroscience, Bachelor of Science

      Postgraduate Training

      2024-2025American Cancer Society Postdoctoral Fellow, Experimental Therapeutics, The American Cancer Society, Houston, Texas
      2021-2025Resident Physician, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
      2020-2021Transitional Year Resident Physician, Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

      Licenses & Certifications

      2026American Board of Radiology (ABR) - Radiation Oncology
      2025Drug Enforcement Administration License (DEA)
      2025Texas Medical Board
      2025Basic Life Support (BLS)
      2021Texas Medical Board

      Experience & Service

      Other Professional Positions

      UTHealth Graduate School of Biomedical Sciences Admissions Committee, Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2026 - Present

      Extramural Institutional Committee Activities

      Committee Member, UTHealth Graduate School of Biomedical Sciences Admissions Committee, UT Health Houston, 2026 - Present

      Honors & Awards

      2026 - PresentKomen Career Catalyst Research Award, Komen Foundation
      2026 - PresentCCSG New Faculty Award, Cancer Center Support Grant
      2026 - PresentHirshberg Foundation Seed Grant program, Hirshberg Foundation
      2025 - PresentCPRIT Scholar Award, Cancer Prevention and Research Institute of Texas
      2025 - PresentK08 Mentored Clinical Scientist Development Award, The National Cancer Institute, National Institutes of Health
      2025Brown Award for Resident Excellence in Radiation Oncology, Texas Radiological Society
      2024Jesse H. Jones Endowed Fellowship in Cancer Research, The University of Texas MD Anderson Cancer Center
      2024Annual Meeting Basic Transitional Award in Biology, The American Society for Radiation Oncology
      2024Resident Excellence Award for Professionalism, The University of Texas MD Anderson Cancer Center
      2023 - 2024RSNA Resident Research Award, The Radiological Society of North America
      2023Leading Edge of Cancer Symposium, 1st Place Trainee Research, The James P. Allison Institute at MD Anderson Cancer Center
      2023Annual Meeting Travel Award in Biology, The American Society for Radiation Oncology
      2023AMGEN Award in Basic Science Research, The University of Texas MD Anderson Cancer Center
      2022 - 2024Radiation Oncology Strategic Initiatives Award, The University of Texas MD Anderson Cancer Center
      2022Mary Fletcher Memorial Award For Patient Care, The University of Texas MD Anderson Cancer Center
      2021Intern of the Year Award, Memorial Sloan Kettering Cancer Center
      2019Titus Munson Coan Prize for Excellence in Research, Columbia University
      2018 - 2020F30 Ruth L. Kirschstein Predoctoral NRSA, The National Cancer Institute, National Institutes of Health
      2018Cellular, Molecular & Biomedical Studies Retreat, 1st Place Talk, Columbia University
      20171st Place MD/PhD Research Symposium Prize, Columbia University
      2011John P. Donoghue Prize Recipient for Neuroscience Research, Brown University

      Professional Memberships

      American Association for Cancer Research

      2023 - Present

      Society for Immunotherapy of Cancer

      2023 - Present

      Radiological Society of North America

      2020 - Present

      American Society of Clinical Oncology

      2020 - Present

      American Society for Radiation Oncology

      2019 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2025. Microbial Mimicry for Immunotherapy: A CD47-ADC That Ignites Myeloid Functionalities. Invited. James P. Allison Institute Seminar Series. Houston, Texas, US.
      2. 2023. Listeria weaponizes antitumor immune responses for T cell immunity. Invited. The Leading Edge of Cancer Symposium. Houston, TX, US.
      3. 2023. Opportunities to Advance Best Clinical Practices for SGM Patients Through Staff Education and Data Collection. Invited. Psychiatry Educational Lecture Series. Houston, Texas, US.
      4. 2023. Conjugation of Listeriolysin O to CD47: Harnessing Listeria to Weaponize Macrophages Against Tumor Cells. Invited. Trainee Research Day. Houston, Texas, US.
      5. 2017. Nuclear actin polymerization drives DNA double-strand break clustering for homology-directed repair. Invited. 43rd Annual Mark Lippard Lecture. New York, NY, US.

      Regional Presentations

      1. 2024. A microbial-inspired antibody-drug conjugate for cancer immunotherapy. Invited. Texas Society of Clinical Oncology Annual Meeting. Dallas, TX, US.
      2. 2024. Listeria-inspired phagosome escape drives STING responses to CD47 blockade. Invited. Texas Radiological Society Annual Meeting. Dallas, TX, US.
      3. 2017. Nuclear actin polymerization drives DNA double-strand break clustering for homology-directed repair. Invited. New York Academy of Sciences Genome Integrity Meeting. New York, NY, US.

      National Presentations

      1. 2024. A Microbial-Inspired Antibody-Drug Conjugate Unleashes Macrophage Functionalities for Cancer Immunotherapy. Invited. American Society for Radiation Oncology Annual Meeting. Washington, D.C, District of Columbia, US.
      2. 2024. Listeria-inspired phagosome escape drives STING responses to CD47 blockade. Poster. American Association for Cancer Research Annual Meeting. San Diego, CA, US.
      3. 2023. Challenges and Opportunities: Piloting SOGI Data Collection and Staff Training in an Academic Medical Center. Invited. The Science of Health Equity Annual Meeting. New York, NY, US.
      4. 2023. Listeriolysin O Drives Innate and Adaptive Immune Responses to CD47 Immunotherapy. Invited. American Society for Radiation Oncology Annual Meeting. San Diego, CA, US.
      5. 2023. The Ethics of Inclusion for Sexual & Gender Minorities in Clinical Trials. Invited. SITC Diversity Roundtable on Clinical Trial Enrollment. Houston, TX, US.
      6. 2022. Harnessing Listeria Toxin to Weaponize Macrophages Against Tumor Cells. Invited. American Society for Radiation Oncology Annual Meeting. San Antonio, TX, US.
      7. 2016. Assessing the contributions of actin filaments to DNA double-strand break repair. Invited. American Society for Cell Biology Annual Meeting. San Diego, CA, US.

      International Presentations

      1. 2018. Nuclear Arp2/3 drives DNA double-strand break clustering for homology-directed repair. Invited. Nuclear Dynamics & Chromatin Organization in Genome Maintenance EMBO conference. Strasbourg, FR.

      Formal Peers

      1. 2025. Oligometastatic Lung Cancer: Cases & Consolidation. Houston, Texas, US.
      2. 2024. Early Stage Non-Small Cell Lung Cancer: Cases & Consolidation. Houston, Texas, US.
      3. 2023. Sarcoma: Cases & Consolidation. Houston, Texas, US.
      4. 2022. Gastric Cancer: Background & Papers. Houston, Texas, US.
      5. 2022. Meningioma: Background & Papers. Houston, Texas, US.
      6. 2022. Radiation Oncology Planning Clinic Course Series. Houston, Texas, US.
      7. 2021. Oropharynx Cancer: Background & Papers. Houston, Texas, US.
      Read More
      Less

      Grant & Contract Support

      Date: 2026 - Present
      Title:An engineered HER2-directed immunotherapy against metastatic breast cancer
      Funding Source:Komen Foundation
      Role:PI
      ID:CCR261550869
      Date: 2026 - 2031
      Title:Engineering STING-activating nanoantioxidants to amplify innate immunity for cancer immunotherapy
      Funding Source:National Cancer Institute
      Role:Co-I
      ID:FP00027900
      Date: 2026 - Present
      Title:Reprogramming Antigen Presentation in Pancreatic Cancer Using Immunostimulatory Antibody-Drug Conjugates
      Funding Source:Hirshberg Foundation for Pancreatic Cancer Research
      Role:PI
      ID:HF-2025-058
      Date: 2025 - Present
      Title:Targeting ecDNA in Antigen-Presenting Cells for Breast Cancer Immunity
      Funding Source:Terri Brodeur Breast Cancer Foundation
      Role:PI
      ID:FP00024715
      Date: 2025 - Present
      Title:Targeting Immune Recognition of ecDNA for Cancer Immunotherapy
      Funding Source:Cancer Prevention and Research Institute of Texas
      Role:PI
      ID:RR250092
      Date: 2025 - Present
      Title:Harnessing ecDNA Detection in Antigen-Presenting Cells for Anti-Tumor Immunity
      Funding Source:National Cancer Institute
      Role:PI
      ID:K08CA296776
      Date: 2024 - 2025
      Title:Listeriolysin O Drives Innate and Adaptive Immune Responses to CD47 Immunotherapy
      Funding Source:The American Society of Clinical Oncology
      Role:PI
      ID:2024YIA-0832385427
      Date: 2024 - 2025
      Title:Enhancing Tumor-Immune Interactions in Breast Cancer via an Immunostimulatory Antibody-Drug Conjugate
      Funding Source:The Society for Immunotherapy of Cancer
      Role:PI
      ID:FP00022175
      Date: 2024 - 2025
      Title:Listeria weaponizes antitumor immune responses to promote T cell immunity
      Funding Source:The American Cancer Society
      Role:PI
      ID:PF-24-1156745-01-ET
      Date: 2023 - 2024
      Title:Listeriolysin O Enhances Radiation Responses to Phagocytosis Checkpoint Blockade
      Funding Source:The Radiological Society of North America
      Role:PI
      ID:RR2334
      Date: 2018 - 2020
      Title:F30 Ruth L. Kirschstein Predoctoral NRSA
      Funding Source:National Cancer Institute
      Role:PI
      ID:CA217049

      Selected Publications

      Peer-Reviewed Articles

      1. Ha, JH, Wang, Y, Ma, Y, Wu, A, Dong, S, Jeong, S, Edwards, J, Chang, M, Chang, YT, Wang, X, Dufilho, M, Najarro Torres, M, McCabe, S, Deng, W, Grippin, A, Weinberg, J, Raza, SM, DeMonte, F, McCutcheon, IE, Prabhu, SS, Ferguson, SD, Ene, CI, Akdemir, KC, Basu, S, Jindal, S, Schrank, B, Hu, J, Goswami, S, Puduvalli, VK, Lang Jr, FF, Huntoon, K, Sharma, P, Kim, BY, Jiang, W. Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma. Nature communications 17(1), 2026. e-Pub 2026. PMID: 41803138.
      2. Gold, BO, Arzola, A, Schrank, B, Morris, VK, Marques, C, Gilliland, J, Atkinson, TM, Holliday, EB. Sexual Toxicity After Chemoradiation for Anal Cancer Among Men Who Have Sex With Men. Advances in Radiation Oncology 11(3), 2026. e-Pub 2026. PMID: 41631252.
      3. Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, Young E, Gupta P, Wang M, Wu A, Jeong SD, Soni D, Weidert F, Xie C, Goldenberg E, Kim A, Zhao C, DeVries A, Castillo P, Lohray R, Rooney MK, Schrank BR, Wang Y, Ma Y, Chang E, Kouzy R, Dyson K, Jafarnia J, Nariman N, Gladish G, New J, Argueta A, Amaya D, Thomas N, Doty A, Chen J, Copling N, Alatrash G, Simon J, Davies AB, Dennis W, Liang R, Lewis J, Wei X, Rinsurongkawong W, Vaporciyan AA, Johns A, Lee J, Lee JH, Sun R, Sharma P, Tran H, Zhang J, Gibbons DL, Wargo J, Kim BYS, Heymach JV, Mendez-Gomez HR, Jiang W, Sayour EJ, Lin SH. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 647(8089):488-497, 2025. e-Pub 2025. PMID: 41125896.
      4. Schrank BR, Kim BYS. Uncovering the hidden landscape of tumour antigens. Nat Rev Immunol 25(7):482, 2025. e-Pub 2025. PMID: 40506469.
      5. Wang Y, Song H, Teng Y, Huang G, Qian J, Wang H, Dong S, Ha J, Ma Y, Chang M, Jeong SD, Deng W, Schrank BR, Grippin A, Wu A, Edwards JL, Zhang Y, Lin Y, Poon W, Wilhelm S, Bi Y, Teng L, Wang Z, Kim BYS, Jiang W. A Generative Artificial Intelligence Copilot for Biomedical Nanoengineering. ACS Nano 19(20):19394–19407, 2025. e-Pub 2025. PMID: 40367350.
      6. Schrank BR, Wang Y, Wu A, Tran N, Lee D, Edwards J, Huntoon K, Dong S, Ha J, Ma Y, Grippin AJ, Jeong SD, Antony A, Chang M, Kang M, Gallup TD, Koong AC, Li J, Yun K, Kim B, Jiang W. An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy. Nature Cancer 6(3):511-527, 2025. e-Pub 2025. PMID: 40000910.
      7. Wu SY, Fang PQ, Fetooh A, Manzar GS, Corrigan KL, Schrank BR, Nasr L, Chihara D, Malpica Castillo LE, Nair R, Steiner RE, Jain P, Neelapu SS, Strati P, Nastoupil LJ, Dabaja BS, Pinnix CC, Gunther JR. Ultra–Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the Lung. Advances in Radiation Oncology 9(12):101648, 2024. e-Pub 2024. PMID: 39524525.
      8. Manzar GS, Cha EE, Corrigan KL, Yoder AK, Schrank BR, Nasr LF, Chihara D, Castillo LM, Nair R, Jain P, Neelapu SS, Rodriguez MA, Strati P, Nastoupil LJ, Gunther JR, Dabaja BS, Pinnix CC, Wu SY, Fang PQ. Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs. Frontiers in Oncology 11(14):1447020, 2024. e-Pub 2024. PMID: 39324011.
      9. Lee D, Huntoon K, Wang Y, Kang M, Lu Y, Jeong SD, Link TM, Gallup TD, Qie Y, Li X, Dong S, Schrank BR, Grippin AJ, Antony A, Ha J, Chang M, An Y, Wang L, Jiang D, Li J, Koong AC, Tainer JA, Jiang W, Kim BY. Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells. Nature Biomedical Engineering 8(5):593-610, 2024. e-Pub 2024. PMID: 38641710.
      10. Schrank BR, Fuller JA, Gallagher CM, Morris VK, Holliday EB, Merriman K, Nguyen L, Weaver L, Nelson K, Chiao E, Koong AC, Hawk E, Chang S. Institution-Wide Retreats Foster Organizational Learning and Action at a Comprehensive Cancer Center. Journal of Cancer Education 39(4):368-373, 2024. e-Pub 2024. PMID: 38468110.
      11. Dong S, Liu X, Bi Y, Wang Y, Antony A, Lee D, Huntoon K, Jeong S, Ma Y, Li X, Deng W, Schrank BR, Grippin AJ, Ha J, Kang M, Chang M, Zhao Y, Sun R, Sun X, Yang J, Chen J, Tang SK, Lee L, Lee AS, Teng L, Wang S, Teng L, Kim BY, Yang Z, Jiang W. Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer. Nature Communications 14(1):6610, 2023. e-Pub 2023. PMID: 37857647.
      12. Wang Y, Deng W, Lee D, Yan L, Lu Y, Dong S, Huntoon K, Antony A, Li X, Ye R, Zhao Y, Zhao F, Schrank BR, Ha J, Kang M, Yang M, Gong P, Lorenzi PL, Tan L, Gallup TD, Tang SK, Yang Z, Li J, Sanford NN, Wang H, Kim BY, Jiang W. Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeutics. Nature Nanotechnology 19(2):255-263, 2023. e-Pub 2023. PMID: 37723279.
      13. You Y, Tian Y, Yang Z, Shi J, Kwak KJ, Tong Y, Estania AP, Cao J, Hsu W, Liu Y, Chiang C, Schrank BR, Huntoon K, Lee D, Li Z, Zhao Y, Zhang H, Gallup TD, Ha J, Dong S, Li X, Wang Y, Lu W, Bahrani E, Lee LJ, Teng L, Jiang W, Lan F, Kim BY, Lee AS. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nature Biomedical Engineering 7(7):887-900, 2023. e-Pub 2023. PMID: 36635419.
      14. Zagelbaum J, Schooley A, Zhao J, Schrank BR, Callen E, Zha S, Gottesman ME, Nussenzweig A, Rabadan R, Dekker J, Gautier J. Multiscale reorganization of the genome following DNA damage facilitates chromosome translocations via nuclear actin polymerization. Nature Structural & Molecular Biology 30(1):99-106, 2022. e-Pub 2022. PMID: 36564591.
      15. Lu Y, Huntoon K, Lee D, Wang Y, Ha J, Qie Y, Li X, Schrank BR, Dong S, Gallup TD, Kang M, Zhao H, An Y, Yang Z, Li J, Kim BY, Jiang W. Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy. Nature Nanotechnology 17(12):1332-1341, 2022. e-Pub 2022. PMID: 36357792.
      16. Rodriguez S, Sahin A, Schrank BR, Al-Lawati H, Costantino I, Benz E, Fard D, Albers AD, Cao L, Gomez AC, Evans K, Ratti E, Cudkowicz M, Frosch MP, Talkowski M, Sorger PK, Hyman BT, Albers MW. Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS-FTD brain, propagate neuronal loss. Science Translational Medicine 13(601):eaaz4699, 2021. e-Pub 2021. PMID: 34233951.
      17. Schrank BR, Aparicio T, Li Y, Chang W, Chait BT, Gundersen GG, Gottesman ME, Gautier J. ARP2/3 drives DNA break clustering for homology-directed repair. Nature 559(7712):61-66, 2018. e-Pub 2018. PMID: 29925947.
      18. Brown TE, Chirila AM, Schrank BR, Kauer AJ. Loss of interneuron LTD and attenuated pyramidal cell LTP in Trpv1 and Trpv3 KO mice. Hippocampus 23(8):662-671, 2013. e-Pub 2013. PMID: 23536486.
      19. Cao L, Schrank BR, Rodriguez S, Benz EG, Moulia TW, Rickenbacher GT, Gomez AC, Levites Y, Edwards SR, Golde TE, Hyman BT, Barnea G, Albers MW. Aβ alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo. Nature Communications 3(1):1009, 2012. e-Pub 2012. PMID: 22910355.
      20. Goel R, Schrank BR, Arora S, Boylan B, Fleming B, Miura H, Newman PJ, Molthen RC, Newman DK. Site-Specific Effects of PECAM-1 on Atherosclerosis in LDL Receptor–Deficient Mice. Arteriosclerosis Thrombosis & Vascular Biology 28(11):1996-2002, 2008. e-Pub 2008. PMID: 18669884.

      Invited Articles

      1. Schrank, BR, Colbert, LE. Genomic biomarkers predict response to combined ATR inhibition and radiotherapy. Clinical Cancer Research 30(24):5505-5507, 2024. e-Pub 2024. PMID: 39422899.
      2. Wang Y, Schrank BR, Jiang W, Kim BYS. Learning what keeps nanomedicines in tumours. Nature Biomedical Engineering, 2024. e-Pub 2024. PMID: 39271934.

      Review Articles

      1. Schrank, BR, Gautier, J. Assembling nuclear domains: Lessons from DNA repair. Journal of Cell Biology 218(8):2444-2455, 2019. e-Pub 2019. PMID: 31324649.

      Other Articles

      1. Zagelbaum J, Schooley A, Zhao J, Schrank BR, Callen E, Zha S, Gottesman ME, Nussenzweig A, Rabadan R, Dekker J, Gautier J Author Correction: Multiscale reorganization of the genome following DNA damage facilitates chromosome translocations via nuclear actin polymerization. Nat Struct Mol Biol 30(7):1048, 2023. PMID: 37059902.

      Editorials

      1. Sherry AD, Rooney MK, Bernard V, Seo A, Marqueen KE, Schrank BR. Residency Interviews in Radiation Oncology After COVID-19: Perspectives From Recently Matched Applicants. International Journal of Radiation Oncology* Biology* Physics 108(2):452-454, 2020. PMID: 32890530.

      Abstracts

      1. Schrank, BR, Wang, Y, Jiang, W. A Microbial-Inspired Antibody-Drug Conjugate Unleashes Macrophage Functionalities for Cancer Immunotherapy. American Society for Radiation Oncology 120(2):S96-S97, 2024. e-Pub 2024.
      2. Schrank, BR, Wang, Y, Antony, A, Jiang, W. Listeria-inspired phagosome escape drives STING responses to CD47 blockade. American Association for Cancer Research 84(6):725, 2024. e-Pub 2024.
      3. Schrank, BR, Wang, Y, Antony, A, Jiang, W. Listeriolysin O Drives Innate and Adaptive Immune Responses to CD47 Immunotherapy. American Society for Radiation Oncology 117(2):S104, 2023. e-Pub 2023.
      4. Schrank, BR, Wang, Y, Jiang, W. Conjugation of Listeriolysin O to Anti-CD47 mAb: Harnessing Listeria Toxin to Weaponize Macrophages against Tumor Cells. American Society for Radiation Oncology 114(3):S42, 2022. e-Pub 2022.
      5. Schrank, BR, Casado, TA, Gautier, J. Understanding the role of actin filaments in DNA double-strand break repair. American Society of Cell Biology 27, 2016. e-Pub 2016.
      Read More
      Less

      Patient Reviews


      CV information above last modified August 07, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Schrank Laboratory

      • Central Nervous System (CNS) Radiation Oncology department

      • Radiation Oncology department

      • Radiation Oncology division

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top